4 в устата и дисфагия, които са съобщени с честота съответно 44% и 35%.
The two most commonly reported undesirable effects in a Phase IV comparative clinical study among toxin naïve patients treated with NeuroBloc 10,000 U to 15,000 U were dry mouth and dysphagia, which were reported at a frequency of 44% and 35%, respectively.